HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

933.888

-1.516-0.16%

Number of Gainers:4

Number of Losers:12

Number of Flat:1

PE:- -

High:943.269

Open:936.194

Low:926.980

Close:935.404

Volume:277.30M

Turnover:2.51B

Market Cap:628.70B

Float Cap:522.84B

Loading ...

Shanghai Fosun Pharma - Recently, Marketing Registration Application for Gr1803 Injection Has Been Approved with Conditions by Nmpa China

THOMSON REUTERS

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live

Healthcare Sector Set for Selective Gains in Second Half, Says Great Wall Fund Manager

Sihuan Pharma Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 0.81

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS

Fosun Pharma Completes HK$3.587 Million Share Buyback on August 27

JD Health International Stock Falls 1.5% in Hong Kong

Alibaba Health Information Technology Stock Falls 1.6% in Hong Kong

Huawei Plans for More AI Pharma Tie-Ups, Says Healthcare President

AH Premium Rankings for August 27: A Market Overview

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.

Shanghai Junshi Biosciences Estimates 35 Million Yuan in Related-Party Transactions

MT Newswires Live

Analysts Have Been Trimming Their Sinopharm Group Co. Ltd. (HKG:1099) Price Target After Its Latest Report

Simply Wall St.

Press Release: Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma

Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss

Shandong Xinhua Pharmaceutical (SEHK:719) Stock Can Margins Recover After Profit Halved

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1515/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":933.88794,"timestamp":1787904511585,"preClose":935.404,"halted":0,"volume":277295395,"delay":0,"changeRate":-0.001621,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-1.516052,"latestTime":"08-28 16:00:00","open":936.19434,"high":943.2685,"low":926.97974,"amount":2509932416.5,"amplitude":0.017414,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"pbRate":1.403188,"peRate":17.015388,"turnoverRate":0.003578,"increases":4,"decrements":12,"flats":1,"marketCap":628696667456,"floatMarketCap":522843441088},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":943.2685,"amplitude":0.017414,"preClose":935.404,"low":926.97974,"pbRate":"1.403188","latestPrice":933.88794,"volume":277295395,"delay":0,"open":936.19434,"prevYearClose":1190.107,"prevWeekClose":933.888,"prevMonthClose":925.972,"prevQuarterClose":802.777,"fiveDayClose":942.615,"twentyDayClose":925.972,"sixtyDayClose":918.123,"secType":"PLATE","market":"HK","turnoverRate":0.003578,"peRate":17.015388,"marketCap":628696667456,"floatMarketCap":522843441088,"timestamp":1787904511585,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":4,"down":12,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662709438","title":"Shanghai Fosun Pharma - Recently, Marketing Registration Application for Gr1803 Injection Has Been Approved with Conditions by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662709438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662709438?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:06","pubTimestamp":1787828777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK0183","BK0239","BK0187","BK0012","BK0196","600196","BK0188","BK0096","BK1515","BK0175","BK1593","BK0028","BK0060","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662457709","title":"CSPC Pharma Gets Trial Nod for Weight Management Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662457709","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662457709?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:05","pubTimestamp":1787828740,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  obtained clinical trial approval for the SYH2092 injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The product has the potential to bring significant clinical benefits for weight management in patients with obesity and improve glycaemic control in patients with type 2 diabetes mellitus.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0314109678.HKD","LU1226287529.USD","HK0000165453.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU0072913022.USD","LU0140636845.USD","IE0008369823.USD","KURE","LU1993786604.SGD","LU0880133367.SGD","LU1226288253.USD","LU1960683339.HKD","IE00BZ08YT58.USD","LU0067412154.USD","LU0501845795.SGD","BK1521","LU1813983027.USD","LU0315179316.USD","LU2039709279.SGD","IE00B031HY20.USD","BK1515","LU1152091168.USD","LU1226287792.SGD","BK1191","LU1152091754.HKD","SG9999004220.SGD","IE00BZ08YS42.EUR","LU1328277881.USD","LU0326950275.SGD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1951186391.HKD","LU1807302812.USD","LU1008478684.HKD","LU1226287875.USD","LU1226288170.HKD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101395901","title":"Healthcare Sector Set for Selective Gains in Second Half, Says Great Wall Fund Manager","url":"https://stock-news.laohu8.com/highlight/detail?id=1101395901","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101395901?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:41","pubTimestamp":1787827277,"startTime":"0","endTime":"0","summary":"After a period of correction and consolidation, the healthcare sector has shown robust performance over the past two months, with the once-prominent \"golden track\" seemingly returning to mainstream...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","IBBQ","06978","MEDX","BK1161","09939","LNGR","159992","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705289","title":"Sihuan Pharma Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 0.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705289","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705289?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:34","pubTimestamp":1787826855,"startTime":"0","endTime":"0","summary":"Sihuan Pharma files HKEX next-day return disclosing share repurchase at HKD 0.81Sihuan Pharmaceutical repurchased 10,000,000 ordinary shares on Aug. 27, holding all as treasury shares.Buyback price ra","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL6cXYkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","00460","BK1191","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191071495","title":"CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1191071495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191071495?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826628,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its developed SYH2092 injection has received approval from China's National Medical Products Administration to proceed with clinical trials within the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU0140636845.USD","LU1008478684.HKD","LU1152091754.HKD","IE00BZ08YS42.EUR","BMED","LU0067412154.USD","LU0314109678.HKD","LU0326950275.SGD","LU0880133367.SGD","IE00B031HY20.USD","LU1807302812.USD","LU1960683339.HKD","IE00B543WZ88.USD","01093","PSYK","IE0008368742.USD","IE00B5MMRT66.SGD","LU1328277881.USD","LU1226287875.USD","SG9999004220.SGD","LU1951186391.HKD","LU1152091168.USD","IBBQ","HK0000165453.HKD","LU0315179316.USD","LU1813983027.USD","IE0008369823.USD","IE00BZ08YT58.USD","LU1226288253.USD","LU0072913022.USD","IBBJ","LU1226287792.SGD","LU1226288170.HKD","BK1191","IE00BZ08YR35.GBP","LU0501845795.SGD","MDTX","BK1515","LU1993786604.SGD","LU1226287529.USD","LU2039709279.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703286","title":"CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703286?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825977,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2092 amylin agonist injectionCSPC won China NMPA clearance to start clinical trials of SYH2092, an amylin receptor agonist injection for obesity.Program ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL60gfrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","BK1515","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","KURE","LU0067412154.USD","LU1226287875.USD","IE0008368742.USD","LU1226288253.USD","LU1152091168.USD","IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","BK1521","LU0314109678.HKD","LU1008478684.HKD","LU0315179316.USD","SG9999004220.SGD","LU1807302812.USD","LU1960683339.HKD","LU2039709279.SGD","LU0072913022.USD","LU0140636845.USD","LU1328277881.USD","LU1226288170.HKD","LU1226287792.SGD","LU1951186391.HKD","IE0008369823.USD","LU1226287529.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE00B543WZ88.USD","LU1813983027.USD","LU1152091754.HKD","LU1993786604.SGD","LU0501845795.SGD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703472","title":"CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703472?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825949,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0315179316.USD","LU1960683339.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287875.USD","LU1226288253.USD","LU1993786604.SGD","LU0314109678.HKD","01093","LU1813983027.USD","LU2039709279.SGD","BK1521","LU0140636845.USD","IE00BZ08YS42.EUR","LU1807302812.USD","BK1515","IE00BZ08YR35.GBP","LU1328277881.USD","HK0000165453.HKD","LU0880133367.SGD","LU0072913022.USD","LU1152091754.HKD","LU1008478684.HKD","BK1191","IE0008368742.USD","LU1951186391.HKD","LU1226287792.SGD","LU1226288170.HKD","IE0008369823.USD","LU1226287529.USD","LU1152091168.USD","LU0501845795.SGD","IE00BZ08YT58.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE00B543WZ88.USD","KURE","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471703","title":"CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825949,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1951186391.HKD","HK0000165453.HKD","BK1191","LU0314109678.HKD","LU0067412154.USD","01093","IE00BZ08YS42.EUR","IE0008369823.USD","LU1226288170.HKD","LU1328277881.USD","LU1226287529.USD","LU1807302812.USD","LU1226287875.USD","LU1960683339.HKD","LU1008478684.HKD","BK1521","IE00BZ08YT58.USD","LU1226287792.SGD","LU1226288253.USD","LU0140636845.USD","LU2039709279.SGD","LU0072913022.USD","LU0315179316.USD","LU1813983027.USD","LU1993786604.SGD","LU0326950275.SGD","KURE","IE00B5MMRT66.SGD","LU0501845795.SGD","SG9999004220.SGD","IE00B543WZ88.USD","LU0880133367.SGD","IE0008368742.USD","IE00B031HY20.USD","LU1152091754.HKD","BK1515","IE00BZ08YR35.GBP","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132782268","title":"Fosun Pharma Completes HK$3.587 Million Share Buyback on August 27","url":"https://stock-news.laohu8.com/highlight/detail?id=1132782268","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132782268?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:40","pubTimestamp":1787823619,"startTime":"0","endTime":"0","summary":"Fosun Pharma (02196) has announced that on August 27, 2026, it repurchased 217,000 shares of its stock for a total consideration of HK$3.587 million.The buyback transaction reflects the company's...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0096","BK0196","600196","BK1593","BK0060","02196","BK0175","BK0183","BK0187","BK0188","BK1515","BK1191","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662710657","title":"JD Health International Stock Falls 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2662710657","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662710657?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:33","pubTimestamp":1787819580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. slipped 1.5% to 36.74 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.3% to 25565.74.This was the stock's second consecutive day of losses.JD Health International Inc. closed 49% short of its 52-week high of HK$71.70, which the company achieved Jan. 15.Trading volume totaled 6.2 million shares, compared to the 50-day average of 10.7 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ62798434.SGD","BK1583","02800","MCHmain","513600","07500","07300","LU0051755006.USD","09115","02833","SGXZ86797644.SGD","86618","HHImain","LU0456827905.SGD","MHImain","BK1515","BK1589","HSTECH","BK1591","BK1247","BK1571","BK1615","03037","83115","82800","HSI","07200","06618","03419","03115","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771059","title":"Alibaba Health Information Technology Stock Falls 1.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771059?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:32","pubTimestamp":1787819520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Alibaba Health Information Technology Ltd. slipped 1.6% to 3.15 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.3% to 25565.74.This was the stock's second consecutive day of losses.Alibaba Health Information Technology Ltd. closed 60% short of its 52-week high of HK$7.91, which the company achieved Jan. 14.The stock underperformed when compared to some of its competitors, as HKT Trust & HKT Ltd. fell 0.7%.Trading volume totaled 66.0 million shares, compared to the 50-day average of 108.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["83115","HHImain","BK1142","MHImain","513600","BK1189","03419","BK1589","HSI","BK1571","BK1617","BK1584","07300","03115","BK1502","BK1591","BK1501","09115","03037","MCHmain","BK1610","BK1247","00241","07500","02833","02800","BK1615","HK0000165453.HKD","07200","82800","BK1515","HSTECH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771484","title":"Huawei Plans for More AI Pharma Tie-Ups, Says Healthcare President","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771484","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771484?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:25","pubTimestamp":1787819119,"startTime":"0","endTime":"0","summary":"Huawei plans for more AI pharma tie-ups, says healthcare presidentSHANGHAI, Aug 27 (Reuters)-Chinese technology conglomerate Huawei plans to expand its AI cooperation with local pharmaceuticalfirmsint","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O077:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1197","BK1521","00874","BK1606","600332","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159208128","title":"AH Premium Rankings for August 27: A Market Overview","url":"https://stock-news.laohu8.com/highlight/detail?id=1159208128","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159208128?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:24","pubTimestamp":1787819062,"startTime":"0","endTime":"0","summary":"As of the market close on August 27, the latest A-H share premium data reveals notable movements across dual-listed companies. NE Electric (00042), Zhejiang Shibao (01057), and Holly Futures (03678)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00568","03759","LU1366334578.USD","03968","LU0314109678.HKD","BK1214","BK1505","LU0210526637.USD","00991","LU0117841782.USD","LU2476274308.USD","LU0417516738.SGD","LU0589944569.HKD","LU0823426308.USD","BK1514","IE0031814852.USD","LU0228367735.SGD","HK0000306701.USD","LU0266512127.USD","BK1610","03188","LU0214875030.USD","LU0531971595.HKD","LU0868486357.SGD","LU0266512473.USD","LU0417516902.SGD","LU0607220059.USD","LU0082770016.USD","LU0516422952.EUR","IE0008368742.USD","BK1141","LU0348825331.USD","BK1592","LU0455707207.USD","BK1576","SG9999001093.SGD","LU2097828557.USD","BK1209","00553","BK1521","LU1152091754.HKD","00981","BK1240","00895","00300","LU0509642566.USD","BK1163","LU0029875118.USD","IE00B543WZ88.USD","LU0531970944.HKD","LU0862451753.SGD","EWH","LU1481107354.HKD","83188","BK1190","LU0106959298.USD","LU0128522157.USD","BK1110","LU0516423091.SGD","LU2008162690.USD","IE00BVYPNP33.GBP","LU0708995583.HKD","IE00BZ08YT58.USD","LU2045819591.USD","IE0032431581.USD","LU1211504680.USD","LU0543330566.HKD","LU1993786604.SGD","82846","LU0348767384.USD","LU0431992006.USD","LU0039217434.USD","BK1202","BK1522","LU1961090484.USD","LU1504937902.USD","BK1560","LU1064131003.USD","BK1183","BK1544","03328","399300","02827","06869","LU1244550577.SGD","03143","LU0516423174.USD","LU1064131342.USD","LU3063872942.SGD","LU1655091616.SGD","LU1064130708.USD","SGXZ81163826.USD","LU0181495838.USD","LU0456854461.SGD","HK0001040143.USD","BK1171","00811","HK0000306685.HKD","LU0890818403.SGD","BK1125","IE00B5MMRT66.SGD","LU2125910500.SGD","LU0164865239.USD","IE00BVYPNQ40.USD","LU1048596156.SGD","LU1244550221.USD","BK1161","LU0348816934.USD","LU2399975544.HKD","LU0348735423.USD","01057","LU2294711473.HKD","LU1831875114.USD","LU0061477393.USD","BK1552","IE00BZ08YS42.EUR","LU0823426480.USD","09981","03308","IE00B031HY20.USD","LU1807302812.USD","SG9999006597.SGD","BK1149","BK1523","LU0359201612.USD","03296","IE00B3M56506.USD","LU1794554557.SGD","LU1813983027.USD","LU0043850808.USD","01877","BK1530","HK0000352382.USD","IE00B031J352.USD","LU1105468828.SGD","LU2039709279.SGD","LU1251922891.USD","LU1046422090.SGD","LU0082770016.SGD","LU0463099449.HKD","LU0348827113.USD","LU1255011170.USD","02899","LU1282649141.HKD","HK0000320264.USD","83130","LU2097828474.EUR","BK1147","IE00B29SXG58.USD","BK0214","02691","LU0049853897.USD","LU0320764599.SGD","LU2097828805.USD","LU2242644610.SGD","BK1562","LU1675838814.USD","BK1144","LU0348814723.USD","LU1244550494.USD","LU0211977185.USD","LU2778985437.USD","03130","LU1769817096.USD","01033","02338","02218","LU0540923850.HKD","IE00BZ08YR35.GBP","LU0328353924.USD","IE00B0169L03.USD","LU0052750758.USD","BK1170","LU0918141705.HKD","LU0231483743.USD","LU0456827905.SGD","LU1688375341.USD","LU0791591158.USD","00638","LU0821914370.USD","00042","IE00BGHQDM52.EUR","LU0348766576.USD","LU0072913022.USD","IE0034224299.USD","LU2394011477.USD","BK1249","LU0244354667.USD","LU0320764755.SGD","02846","LU2476274720.SGD","LU0359201885.HKD","01812","LU0359202008.SGD","03678","LU0648948544.HKD","SG9999002463.SGD","LU0106252389.USD","BK1614","LU0561508036.HKD","LU0737861772.HKD","SGXZ49509284.SGD","LU1303224171.USD","BK1237","LU0329678170.USD","LU0634319403.HKD","LU0307460666.USD","LU0828237940.HKD","LU0449509016.USD","LU1242518857.USD","BK1198","LU0149534421.HKD","BK1140","LU0096374516.USD","LU1282648689.USD","LU1880383440.USD","BK1526","SG9999004220.SGD","LU1188198961.HKD","LU0469268626.HKD","02475","LU0345780521.USD","02359","03750","LU0640798160.USD","03986","HK0001040168.HKD","06185","LU1023057109.AUD","BK1191","LU0501845795.SGD","LU0672654166.SGD","LU0516422440.USD","LU1224709979.USD","LU0348788117.USD","BK1116","LU0886674414.USD","LU0164939612.USD","06066","LU1366334651.USD","LU1769817179.HKD","LU0348805143.USD","LU2264538146.SGD","LU1152091168.USD","BK1181","LU1988902786.USD","LU0370786039.SGD","HK0000320223.HKD","LU0165289439.USD","01989","LU0543330483.HKD","BK1607","LU0456846285.SGD","LU2097828631.EUR","IE00BMCWC346.EUR","LU1719994722.HKD","01349","SG9999002828.SGD","BK1551","LU0229945570.USD","LU0228659784.USD","BK1537","LU0502904849.HKD","BK1105","LU1770034418.SGD","LU2097828714.EUR","SG9999014674.SGD","LU0918141887.USD","HK0000352291.HKD","LU0315179316.USD","BK1533","SG9999011746.SGD","LU0516422366.SGD","LU0384037296.USD","LU0979878070.USD","LU1226287529.USD","LU0164880469.USD","LU0173614495.USD","BK1507","LU0140636845.USD","LU0326950275.SGD","LU0588546209.SGD","BK1130","BK1574","LU0269904917.USD","BK1231","BK1594","BK1583","LU0488056044.USD","LU0871576103.HKD","LU0345780281.USD","LU0048580855.USD","159982","02768","BK1546","BK1554","LU2177674079.SGD","BK1564","LU0051755006.USD","LU1008478684.HKD","LU0067412154.USD","LU0828237510.HKD","LU1282649810.SGD","IE00BYV24P56.USD","LU1282649067.USD","00187","LU1960683339.HKD","LU0828238088.HKD","LU0620787316.HKD","IE00BF5LJ272.USD","LU0737861699.HKD","LU0593848301.USD","LU1720050803.USD","IE0008369823.USD","LU1242518931.SGD","LU2226246903.HKD","SG9999001226.SGD","LU0791590937.USD","LU1880383366.USD","LU1808992512.USD","LU0880133367.SGD","LU0329678337.USD","LU0797268264.HKD","LU0327786744.USD","LU0287142896.SGD","LU1328277881.USD","LU2148510915.USD","BK1122","BK1193","688981","LU0254981946.USD","LU1115378108.SGD","BK1223","LU0163747925.USD","07233","LU0149721374.USD","01108","BK1506","BK1515","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977171","title":"CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977171","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662977171?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:20","pubTimestamp":1787815224,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (SEHK:1093) is back in focus after reporting half year 2026 results, announcing a higher interim dividend and updating investors on several oncology drug milestones in China.\nThe recent half year 2026 earnings and oncology updates appear to have fed directly into CSPC Pharmaceutical Group’s share price momentum, with a 90 day share price return of 36.85% and a 30 day gain of 14.76% helping lift the stock to HK$9.525. The 3 year total shareholder return of 81.14%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1328277881.USD","LU0501845795.SGD","FEBU","IE00BZ08YT58.USD","KURE","LU0314109678.HKD","DECU","01093","SG9999004220.SGD","LU1993786604.SGD","LU1008478684.HKD","IE00B543WZ88.USD","LU1226287792.SGD","BK1191","LU2039709279.SGD","RGLO","IE00B031HY20.USD","LU0880133367.SGD","GXDW","LU1226288170.HKD","LU1152091168.USD","LU1951186391.HKD","LU0072913022.USD","LU0326950275.SGD","IE0008368742.USD","VGFPF","BK1521","LU1226287529.USD","IE00BZ08YS42.EUR","PMDE","LU1960683339.HKD","DCF","LU0067412154.USD","LU0315179316.USD","LU1813983027.USD","LU0140636845.USD","JOYT","VOTE","IE0008369823.USD","LU1152091754.HKD","LU1807302812.USD","BK1515","HK0000165453.HKD","IE00B5MMRT66.SGD","LU1226288253.USD","IE00BZ08YR35.GBP","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662776198","title":"Shanghai Junshi Biosciences Estimates 35 Million Yuan in Related-Party Transactions","url":"https://stock-news.laohu8.com/highlight/detail?id=2662776198","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662776198?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:20","pubTimestamp":1787815201,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences  estimated related-party transactions totaling 35.0 million yuan with TopAlliance Biosciences and its subsidiaries.The transactions involve product sales, service provisions and acceptance of services, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 2% in recent trade on the Hong Kong bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","01877","BK1161","688180","BK0239","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771265","title":"Analysts Have Been Trimming Their Sinopharm Group Co. Ltd. (HKG:1099) Price Target After Its Latest Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771265?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:45","pubTimestamp":1787813109,"startTime":"0","endTime":"0","summary":"Shareholders might have noticed that Sinopharm Group Co. Ltd. ( HKG:1099 ) filed its interim result this time last...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6031000-choice2-main-header/1585186857496"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/analysts-have-been-trimming-their-sinopharm-group-co-ltd-hkg","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-1099/sinopharm-group-shares/news/analysts-have-been-trimming-their-sinopharm-group-co-ltd-hkg","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RGLO","JOYT","01099","BK1500","FEBU","VOTE","LU0640798160.USD","LU1115378108.SGD","PMDE","DECU","BK1197","BK1515","VGFPF","GXDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727363","title":"Press Release: Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727363","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662727363?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:58","pubTimestamp":1787803080,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 26, 2026  -- Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate updates.FINANCIAL HIGHLIGHTS-- As of June 30, 2026, the company's total revenue was approximately. RMB1,696 million for the first half of 2026 , a 45% increase. compared to 2025, which was made possible by the rise in sales revenue of. pharmaceutical products. In particular, the domestic sales revenue of our. core product, toripalimab, reached approximately RMB1,299 million, around. 36% more than in 2025. In addition, out-licensing revenue also increased. by approximately RMB152 million, an approximately 149% improvement from. -- Total research and development  expenses of the company were. approximately RMB644 million for 2026H1, which was primarily used to. advance the construction of our R&D technology platforms, ex","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01877","BK1161","BK4232","R","BK4022","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135812657","title":"Unpacking ALEBUND-B's First Half Results: The Compounding Growth Logic of a Kidney Disease-Focused Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1135812657","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135812657?lang=en_us&edition=fundamental","pubTime":"2026-08-27 08:04","pubTimestamp":1787789077,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) delivered its inaugural interim results on August 26, marking a significant milestone since its listing, with revenue scaling to 8.6 times the figure reported in the same period...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","159938","09637","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178598132","title":"Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1178598132","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178598132?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:20","pubTimestamp":1787761218,"startTime":"0","endTime":"0","summary":"Shanghai Junshi Biosciences Co., Ltd. has announced its financial results for the first half of 2026, revealing a notable turnaround in profitability.During the reporting period, the company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688180","BK1583","BK1515","BK1161","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745416","title":"Shandong Xinhua Pharmaceutical (SEHK:719) Stock Can Margins Recover After Profit Halved","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745416?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:24","pubTimestamp":1787757843,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical came into this earnings print with a stock under pressure, down about 9.7% over the past month and 3.0% over the last week, even after closing at HK$5.75 on 26 August. The market has been treating the company as a low-growth, margin-challenged drug maker trading on a discounted P/E.\nThe headline this quarter is another profit squeeze. Q2 2026 revenue landed at ¥1,934.5m yet net income reached only ¥65.2m, which implies thin profitability for a pharmaceutical...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-719/shandong-xinhua-pharmaceutical-shares/news/shandong-xinhua-pharmaceutical-sehk719-stock-can-margins-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-719/shandong-xinhua-pharmaceutical-shares/news/shandong-xinhua-pharmaceutical-sehk719-stock-can-margins-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","00719","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":3,"totalSize":272,"code":"91000000","status":"200"}]}}